Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rapid diagnostics first, then revolutionary antibiotics will follow

This article was originally published in Clinica

Executive Summary

Rapid diagnostics that can be used to identify the right study patients, enrich clinical trials, improve clinical care and stewardship, and help get drugs approved for limited populations will be an essential factor to reinvigorating the antibiotic pipeline and quelling the tide of multi-drug resistant infections, stakeholders echoed over and over again at a recent workshop organized by the National Institutes of Health and the US FDA.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT101822

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel